DiscoveryBioMed Committed to Polycystic Kidney Disease Research Reagent Development and PKD-Specific Drug Discovery as a Core Disease with Unmet Need

BIRMINGHAM, Ala.--(BUSINESS WIRE)--DiscoveryBioMed, Inc. (DBM) will act as a Cell Culture and Engineering Core for a larger program project grant awarded to the Johns Hopkins University School of Medicine designed to generate valuable reagents to study the basic, applied and translational science of polycystic kidney disease (PKD). The Johns Hopkins PKD Center was one of four such P30 Centers funded by the National Institutes of Health (NIH) and its National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK).